Last reviewed · How we verify

Ethinylestradiol / Norethisterone

University of Edinburgh · FDA-approved active Small molecule

Ethinylestradiol and norethisterone work together as a combined oral contraceptive by suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis.

Ethinylestradiol and norethisterone work together as a combined oral contraceptive by suppressing ovulation through hormonal feedback on the hypothalamic-pituitary-ovarian axis. Used for Contraception, Regulation of menstrual cycle, Treatment of menorrhagia.

At a glance

Generic nameEthinylestradiol / Norethisterone
Also known asLoestrin 30, Galen Ltd, UK
SponsorUniversity of Edinburgh
Drug classCombined oral contraceptive
TargetEstrogen receptor and progesterone receptor
ModalitySmall molecule
Therapeutic areaContraception / Reproductive Health
PhaseFDA-approved

Mechanism of action

Ethinylestradiol is a synthetic estrogen that inhibits follicle-stimulating hormone (FSH) secretion, while norethisterone is a synthetic progestin that inhibits luteinizing hormone (LH) secretion and alters the endometrium. Together, they prevent the LH surge necessary for ovulation and create an unfavorable uterine environment for implantation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: